124 related articles for article (PubMed ID: 28537044)
1. Preoperative Statin Use Associated With Lower PSA But Similar Prostate Size and Histopathologic Outcomes: Implications for Active Surveillance?
Stensland K; McBride RB; Leapman M; Hobbs A; Jazayeri SB; Samadi DB
Urol J; 2017 May; 14(3):3064-3070. PubMed ID: 28537044
[TBL] [Abstract][Full Text] [Related]
2. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
Krane LS; Kaul SA; Stricker HJ; Peabody JO; Menon M; Agarwal PK
J Urol; 2010 Jan; 183(1):118-24. PubMed ID: 19913252
[TBL] [Abstract][Full Text] [Related]
3. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
[TBL] [Abstract][Full Text] [Related]
4. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
5. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
6. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
Chao C; Jacobsen SJ; Xu L; Wallner LP; Porter KR; Williams SG
BJU Int; 2013 May; 111(6):954-62. PubMed ID: 23464862
[TBL] [Abstract][Full Text] [Related]
7. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
8. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
10. Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.
Eminaga O; Hinkelammert R; Abbas M; Wötzel F; Eltze E; Bettendorf O; Boegemann M; Semjonow A
Urology; 2015 Oct; 86(4):798-804. PubMed ID: 26255036
[TBL] [Abstract][Full Text] [Related]
11. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy.
Kontraros M; Varkarakis I; Ntoumas K; Deliveliotis C
Urol Int; 2013; 90(3):263-9. PubMed ID: 23548958
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
13. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
15. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
[TBL] [Abstract][Full Text] [Related]
16. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
17. Effect of statin use on biochemical outcome following radical prostatectomy.
Ritch CR; Hruby G; Badani KK; Benson MC; McKiernan JM
BJU Int; 2011 Oct; 108(8 Pt 2):E211-6. PubMed ID: 21453350
[TBL] [Abstract][Full Text] [Related]
18. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.
Bañez LL; Klink JC; Jayachandran J; Lark AL; Gerber L; Hamilton RJ; Masko EM; Vollmer RT; Freedland SJ
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):722-8. PubMed ID: 20160265
[TBL] [Abstract][Full Text] [Related]
19. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
Fowke JH; Motley SS; Barocas DA; Cookson MS; Concepcion R; Byerly S; Smith JA
Cancer Causes Control; 2011 Mar; 22(3):417-26. PubMed ID: 21170754
[TBL] [Abstract][Full Text] [Related]
20. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
